Poolbeg Pharma says it has successfully used artificial intelligence to identify drug targets for the treatment of Respiratory Syncytial Virus (RSV).
The programme identified the RSV drug treatment candidates in just 10 months, the company said in a stock exchange announcement this morning.
"AI-led drug discovery can accelerate the timeline achievable which reduces costs while also decreasing risks and providing a higher likelihood of success in bringing groundbreaking therapies to patients," Poolbeg said.
Poolbeg said its team of scientific experts have reviewed the comprehensive data package obtained from the lab-based analysis and has prioritised a select number of the RSV drug candidates that were analysed.
It said it is actively exploring the most effective way to progress the prioritised drug candidates in order to generate value.
"Poolbeg believes the data obtained reflects the high potential of this AI-led programme and supports its partnering efforts," it added.
Jeremy Skillington, chief executive of Poolbeg Pharma, said the positive outputs from this analysis, and the successful prioritisation of its RSV drug candidates, is a testament to the power of its AI-led drug discovery programme.
"As we engage in partnering discussions, these results position Poolbeg as a key player in the evolving landscape of AI-driven drug discovery," the CEO added.
{Categories} _Category: Applications,*ALL*{/Categories}
{URL}https://www.rte.ie/news/business/2023/1220/1422986-poolbeg-pharmas-rsv-drug-targets/{/URL}
{Author}unknown{/Author}
{Image}https://img.rasset.ie/001727cf-800.jpg{/Image}
{Keywords}Business{/Keywords}
{Source}Applications{/Source}
{Thumb}{/Thumb}
